McGill researchers overcome chemotherapy resistance in the labJune 30, 2008Re-purposed Malaysian folk medication reduces resistance to cancer treatments Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI). Dr. Jerry Pelletier, PhD candidate Marie-Eve Bordeleau, and post-doctoral fellow Francis Robert, of the Department of Biochemistry and the McGill Cancer Centre - along with colleagues from Boston University, the Sloan-Kettering Cancer Center, the University of Vienna and the Howard Hughes Medical Institute - conducted an extensive study on a class of natural products known as cyclopenta benzofuran flavaglines (CBF).
Working with mice genetically modified to mimic human leukemias, they discovered that one particular CBF compound, silvestrol, can effectively re-sensitize tumors to chemotherapy, making them susceptible to the killing effects of anticancer drugs. "One of the major problems with cancer therapy is that the tumours either fail to respond or stop responding over time to various chemotherapy drugs," Pelletier said. "One reasonable explanation for why this happens is the normal process of protein synthesis in the cell is usurped, principally because cancer cells grow faster and have higher metabolic needs. The normal checks and balances are no longer present." Pelletier's lab at the Department of Biochemistry and McGill Cancer Centre focuses on high-throughput assays of various compounds to determine their anti-cancer effectiveness. One that showed promise was silvestrol, a natural compound derived from Aglaia silvestris, a large genus of trees and shrubs found in Malaysia, South China and some Pacific islands. It has been used in Malaysian folk medicine for generations, but never as a cancer therapy. "We made a conscious decision early on in our research to also screen for natural products," Pelletier says. "Silvestrol is not a synthetic compound you can buy from commercial suppliers." In the lab, Pelletier explained, silvestrol therapy re-sensitized leukemia cells which had already demonstrated resistance to the chemotherapy agent doxorubicin. "Essentially, we have turned off the cancer cell's survival signals, which is associated with resistance," he said. However, he cautioned, though synthetic silvestrol is now starting to become available, trials in humans and possible treatments are still many years away. McGill University | |||||||||||||||||||||
|
Related Chemotherapy Current Events and Chemotherapy News Articles Hodgkin lymphoma -- new characteristics discovered Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern. Bisphenol A linked to chemotherapy resistance Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists. Pediatric study finds alternatives for radiation of low-grade brain tumors A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. Mayo researchers explore issues related to multiple myeloma treatment Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. News from Cancer: Disparities in head and neck cancer patients A new analysis finds considerable disparities in survival related to race and socio-economic status among patients with head and neck cancer. Nanodiamond drug device could transform cancer treatment A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed. Children's National researchers develop novel anti-tumor vaccine A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice. Surgical treatment provides new option for some colorectal cancer patients Research out of Wake Forest University School of Medicine suggests that a surgical technique not traditionally used in advanced abdominal cancer may be a viable treatment option for some patients previously thought to be untreatable, offering the real possibility of extending survival for those patients. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs In pre-clinical studies, vitamin C appears to substantially reduce the effectiveness of anticancer drugs, say researchers at Memorial Sloan-Kettering Cancer Center. Hepatitis B exposure may increase risk for pancreatic cancer In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer. More Chemotherapy Current Events and Chemotherapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||